CRNX Relative Valuation
CRNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRNX is overvalued; if below, it's undervalued.
Historical Valuation
Crinetics Pharmaceuticals Inc (CRNX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.08. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：47.42
Fair
-8.49
PE
1Y
3Y
5Y
Trailing
Forward
-7.09
EV/EBITDA
Crinetics Pharmaceuticals Inc. (CRNX) has a current EV/EBITDA of -7.09. The 5-year average EV/EBITDA is -5.48. The thresholds are as follows: Strongly Undervalued below -11.37, Undervalued between -11.37 and -8.42, Fairly Valued between -2.53 and -8.42, Overvalued between -2.53 and 0.42, and Strongly Overvalued above 0.42. The current Forward EV/EBITDA of -7.09 falls within the Historic Trend Line -Fairly Valued range.
-6.00
EV/EBIT
Crinetics Pharmaceuticals Inc. (CRNX) has a current EV/EBIT of -6.00. The 5-year average EV/EBIT is -5.73. The thresholds are as follows: Strongly Undervalued below -11.34, Undervalued between -11.34 and -8.54, Fairly Valued between -2.92 and -8.54, Overvalued between -2.92 and -0.12, and Strongly Overvalued above -0.12. The current Forward EV/EBIT of -6.00 falls within the Historic Trend Line -Fairly Valued range.
127.89
PS
Crinetics Pharmaceuticals Inc. (CRNX) has a current PS of 127.89. The 5-year average PS is 939.52. The thresholds are as follows: Strongly Undervalued below -1569.26, Undervalued between -1569.26 and -314.87, Fairly Valued between 2193.92 and -314.87, Overvalued between 2193.92 and 3448.31, and Strongly Overvalued above 3448.31. The current Forward PS of 127.89 falls within the Historic Trend Line -Fairly Valued range.
-13.19
P/OCF
Crinetics Pharmaceuticals Inc. (CRNX) has a current P/OCF of -13.19. The 5-year average P/OCF is -9.91. The thresholds are as follows: Strongly Undervalued below -18.32, Undervalued between -18.32 and -14.12, Fairly Valued between -5.71 and -14.12, Overvalued between -5.71 and -1.50, and Strongly Overvalued above -1.50. The current Forward P/OCF of -13.19 falls within the Historic Trend Line -Fairly Valued range.
-11.08
P/FCF
Crinetics Pharmaceuticals Inc. (CRNX) has a current P/FCF of -11.08. The 5-year average P/FCF is -9.31. The thresholds are as follows: Strongly Undervalued below -16.63, Undervalued between -16.63 and -12.97, Fairly Valued between -5.66 and -12.97, Overvalued between -5.66 and -2.00, and Strongly Overvalued above -2.00. The current Forward P/FCF of -11.08 falls within the Historic Trend Line -Fairly Valued range.
Crinetics Pharmaceuticals Inc (CRNX) has a current Price-to-Book (P/B) ratio of 4.18. Compared to its 3-year average P/B ratio of 3.84 , the current P/B ratio is approximately 8.76% higher. Relative to its 5-year average P/B ratio of 3.67, the current P/B ratio is about 13.94% higher. Crinetics Pharmaceuticals Inc (CRNX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.61%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -9.04% , the current FCF yield is about -100.00% lower.
4.18
P/B
Median3y
3.84
Median5y
3.67
-7.94
FCF Yield
Median3y
-8.61
Median5y
-9.04
Competitors Valuation Multiple
The average P/S ratio for CRNX's competitors is 0.00, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRNX decreased by 7.26% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 143.00K.
The secondary factor is the Margin Expansion, contributed 333.95%to the performance.
Overall, the performance of CRNX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Crinetics Pharmaceuticals Inc (CRNX) currently overvalued or undervalued?
What is Crinetics Pharmaceuticals Inc (CRNX) fair value?
How does CRNX's valuation metrics compare to the industry average?
What is the current P/B ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Dec 05 2025?
What is the current FCF Yield for Crinetics Pharmaceuticals Inc (CRNX) as of Dec 05 2025?
What is the current Forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Dec 05 2025?